Krystal Biotech saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 70 to 77.
IBD's unique rating identifies share price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
History shows that the best stocks often have an RS Rating north of 80 as they launch their largest climbs. See if Krystal Biotech can continue to rebound and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Krystal Biotech is building a consolidation with a 219.34 entry. See if the stock can clear the breakout price in volume at least 40% above average.
Krystal Biotech reported 0% EPS growth in the latest quarterly report. Revenue rose 0%. Look for the next report on or around Nov. 4.
The company earns the No. 41 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and United Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
